Market Intelligence, Clinical Progress, and High-Purity Reagents for Apoptosis Imaging, Antiphospholipid Syndrome, and Targeted Delivery Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANXA5 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANXA5 Recombinant Protein (Wild-Type & Calcium-Binding Mutants) High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. HEK293 Expressed. |
View ANXA5 Products |
| Gene Delivery | ANXA5 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Calcium-binding domain intact. |
View ANXA5 Products |
| Benchmark Ab | Anti-ANXA5 Recombinant Reference Antibody Sequence-verified positive control for SPR/BLI and capture assays; includes IgG/IgM for APS research. |
View ANXA5 Products |
| Validator | ANXA5 siRNA Set For knockdown verification and pathway analysis. |
View ANXA5 Products |
| Related Target A | CASP3 Downstream apoptosis effector for mechanistic synergy. |
View CASP3 Products |
| Related Target B | BCL2 Apoptosis regulator for resistance bypass studies. |
View BCL2 Products |
| Related Target C | ANXA1 (Annexin A1) Same superfamily; key comparator for selectivity and anti-inflammatory pathway studies. |
View ANXA1 Products |
| Related Target D | MERTK Receptor for phosphatidylserine recognition; efferocytosis axis partner. |
View MERTK Products |
| Related Target E | TIMD4 (TIM-4) Phosphatidylserine receptor, synergistic apoptosis clearance. |
View TIMD4 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Calcium-Dependent Phospholipid Binding & Conformational Integrity | Sequence Verified Wild-Type and D226A/D279A Calcium-Binding Mutants; HEK293 Expressed for native folding. |
| In Vivo Animal Model Toxicity | Endotoxin Controlled (<1 EU/µg) formulations ideal for cellular and in vivo assays. |
| Cross-Species Preclinical Evaluation (Human/Mouse/Cyno) | Human/Mouse/Cyno ortholog proteins available with >95% purity; Endotoxin controlled. |
| Annexin Family Counter-Screening (ANXA1, ANXA2 Off-Target Risk) | Homolog panel proteins strictly verified by mass spec for selectivity assays. |
| Lack of Standardized Controls | Sequence Verified recombinant benchmark antibodies for reliable positive controls. |
| High-Concentration Stability for Imaging Probe Conjugation | Aggregate-controlled by SEC; Endotoxin <1 EU/µg. |
| Antiphospholipid Syndrome (APS) Assay Specificity | Validated siRNA and calcium-free negative controls; anti-ANXA5 IgG/IgM benchmarks included. |
Live ANXA5 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (Annexin V)
- ➤ View Active Clinical Trials (Annexin A5)
- ➤ Latest Therapeutic & Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ANXA5-targeted therapeutics and diagnostics is intensifying, with major players shifting focus from generic apoptosis detection reagents toward clinical-grade imaging probes, antiphospholipid syndrome (APS) immunomodulation, and targeted drug delivery vehicles. First-generation radiolabeled Annexin V agents (e.g., Tc-99m Annexin V) are advancing through cardiovascular and oncology trials, enabling real-time apoptosis imaging. Concurrently, recombinant ANXA5 variants (e.g., Diannexin dimers) are being developed as therapeutic "protection shields" against ischemia-reperfusion injury and thrombosis by blocking coagulation factor binding to exposed phosphatidylserine (PS). Engineered ANXA5–drug conjugates and fusion proteins are targeting PS externalization on tumor vasculature and apoptotic cells, creating a robust pipeline for novel oncology and cardiovascular interventions. Ongoing R&D also includes Fc-engineered variants and epitope-specific antibodies that modulate the coagulation–apoptosis interface, particularly for autoimmune conditions such as APS. The next wave of innovation will likely combine ANXA5-based imaging with immune checkpoint inhibitors to guide combination therapy dosing.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Fusion Protein / Dimer (e.g., Diannexin) | Pharming Group, MTI | Ischemia-Reperfusion, Thrombosis, Organ Transplantation | Binding kinetics & Avidity (Need High-Purity Recombinant ANXA5 with intact calcium coordination) |
| Targeted Delivery (ADC/Conjugate) | Various Biotechs, Targeted Therapy Companies | Solid Tumors (PS on Tumor Vasculature) | Internalization Assay (Need precisely quantified wild-type/mutant proteins, fluorescent-labeled derivatives) |
| Radiopharmaceutical / Imaging Probe | Advanced Accelerator Applications, Theseus Imaging, Academic Centers | Oncology Imaging, Apoptosis Detection, Cardiovascular Events | Target specificity & Chelation Stability (Need Sequence Verified standards, calcium-dependent PS binding) |
| Therapeutic Recombinant Protein | Translational Biotechs | Antiphospholipid Syndrome (APS), Sepsis | Calcium-Dependent PS Binding Assay (Need Ca2+ responsive WT & mutant controls) |
| Anti-ANXA5 Monoclonal Antibody | Early-Stage Biotech / Academia | Autoimmune Thrombosis, APS, Recurrent Miscarriage | Selectivity Assay vs ANXA1/ANXA2 (Need homolog panel) & Epitope Mapping |
| Drug Delivery Vector (PS-Targeted) | Various Biotechs | Oncology (Targeting PS on Tumor Vasculature) | Internalization Assay (Need fluorescent/labeled ANXA5 derivatives with preserved binding) |
Next-Generation Considerations: Molecular Differentiation & Assay Strategy
For best-in-class ANXA5 programs, key differentiation factors include:
- Affinity & Avidity: Balancing high-avidity multimerization (e.g., dimers vs. monomers) to avoid non-specific platelet aggregation while ensuring robust PS binding under physiological Ca2+ concentrations.
- Delivery & PK: Extending half-life via Fc-fusion, PEGylation, or albumin-binding domain (ABD) without disrupting Ca2+-binding sites. High-concentration stability and viscosity testing are critical for subcutaneous formulation.
- Safety & Specificity: Annexin family homologs (ANXA1, ANXA2) share conserved core domains; off-target risks must be screened. Tissue cross-reactivity and coagulation balance assessments are essential for systemic therapies.
- Mechanism of Action: For imaging probes, labeling must preserve Ca2+/PS pocket integrity. For therapeutic fusions, Fc-mediated effector functions (ADCC/ADCP) must be validated not to interfere with natural efferocytosis.
TarMart supports these needs with: (i) sequence-verified WT and mutant (D226A/D279A) proteins, (ii) cross-species orthologs (human/mouse/cyno) with >95% purity and <1 EU/µg endotoxin, (iii) validated siRNA and benchmark antibodies, and (iv) ANXA1/ANXA2 homolog panels for selectivity screening.